• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Diagnostic Testing to Identify PD-L1 Inhibitor Response in Lung Cancer

Video

Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses using PD-L1 expression on a tumor to identify patient response to treatment.

Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses using PD-L1 expression on a tumor and its benefits.

Transcript

We are pre-identifying patients by PD-L1 expression on the tumor; it’s an immunohistochemical assay and it’s fairly easy to do. High levels of PD-L1 expression do tend to correlate with benefit—it’s not a perfect biomarker; there’s both false positives and negatives. It’s not a binary biomarker, like EGFR mutation testing, but it does provide some guide to who is more likely to benefit.

The approval of pembrolizumab first-line treatment, a single agent in lung cancer was based on KEYNOTE-024 where patients who have more than 50% of PD-L1 expression, which is about a third of non-small cell lung cancer and in those patients, they had a superior response rate, progression-free survival, as well as overall survivor with single-agent pembrolizumab versus chemotherapy.

So, based on that data, and really the standard of care, to test for PD-L1 expression if you’re positive at the 50% threshold and treat with single agent pembrolizumab and not chemotherapy.

Related Videos
Pat Van Burkleo
Jeff Stark, MD, vice president, head of medical immunology, UCB
Robert Groves, MD
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Dr Padma Sripada, Columbia Internal Medicine
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.